

2024-04-02

A chemical screen identifies structurally diverse metal chelators with activity against the fungal pathogen *Candida albicans*

S. Fallah, D. Duncan, K.D. Reichl, M.J. Smith, W. Wang, J.A. Porco, L.E. Brown, L. Whitesell, N. Robbins, L.E. Cowen. 2024. "A chemical screen identifies structurally diverse metal chelators with activity against the fungal pathogen *Candida albicans*." *Microbiology Spectrum*, Volume 12, Issue 4, pp.e0409523-. <https://doi.org/10.1128/spectrum.04095-23>

<https://hdl.handle.net/2144/49013>

Downloaded from DSpace Repository, DSpace Institution's institutional repository

A chemical screen identifies structurally diverse metal chelators with activity against the fungal pathogen *Candida albicans*

Sara Fallah,¹ Dustin Duncan,^{1,2} Kyle D. Reichl,³ Michael J. Smith,³ Wenyu Wang,³ John A. Porco Jr.,³ Lauren E. Brown,³ Luke Whitesell,¹ Nicole Robbins,¹ Leah E. Cowen¹

AUTHOR AFFILIATIONS See affiliation list on p. 6.

ABSTRACT *Candida albicans*, one of the most prevalent human fungal pathogens, causes diverse diseases extending from superficial infections to deadly systemic mycoses. Currently, only three major classes of antifungal drugs are available to treat systemic infections: azoles, polyenes, and echinocandins. Alarming, the efficacy of these antifungals against *C. albicans* is hindered both by basal tolerance toward the drugs and the development of resistance mechanisms such as alterations of the drug's target, modulation of stress responses, and overexpression of efflux pumps. Thus, the need to identify novel antifungal strategies is dire. To address this challenge, we screened 3,049 structurally-diverse compounds from the Boston University Center for Molecular Discovery (BU-CMD) chemical library against a *C. albicans* clinical isolate and identified 17 molecules that inhibited *C. albicans* growth by >80% relative to controls. Among the most potent compounds were CMLD013360, CMLD012661, and CMLD012693, molecules representing two distinct chemical scaffolds, including 3-hydroxyquinolinones and a xanthone natural product. Based on structural insights, CMLD013360, CMLD012661, and CMLD012693 were hypothesized to exert antifungal activity through metal chelation. Follow-up investigations revealed all three compounds exerted antifungal activity against non-*albicans Candida*, including *Candida auris* and *Candida glabrata*, with the xanthone natural product CMLD013360 also displaying activity against the pathogenic mould *Aspergillus fumigatus*. Media supplementation with metallonutrients, namely ferric or ferrous iron, rescued *C. albicans* growth, confirming these compounds act as metal chelators. Thus, this work identifies and characterizes two chemical scaffolds that chelate iron to inhibit the growth of the clinically relevant fungal pathogen *C. albicans*

IMPORTANCE The worldwide incidence of invasive fungal infections is increasing at an alarming rate. Systemic candidiasis caused by the opportunistic pathogen *Candida albicans* is the most common cause of life-threatening fungal infection. However, due to the limited number of antifungal drug classes available and the rise of antifungal resistance, an urgent need exists for the identification of novel treatments. By screening a compound collection from the Boston University Center for Molecular Discovery (BU-CMD), we identified three compounds representing two distinct chemical scaffolds that displayed activity against *C. albicans*. Follow-up analyses confirmed these molecules were also active against other pathogenic fungal species including *Candida auris* and *Aspergillus fumigatus*. Finally, we determined that these compounds inhibit the growth of *C. albicans* in culture through iron chelation. Overall, this observation describes two novel chemical scaffolds with antifungal activity against diverse fungal pathogens.

KEYWORDS metal chelator, fungal pathogen, *Candida*, *Aspergillus*, iron, chemical library

Editor James B. Konopka, Stony Brook University, Stony Brook, New York, USA

Address correspondence to Leah E. Cowen, leah.cowen@utoronto.ca.

L.E.C. and L.W. are co-founders and shareholders in Bright Angel Therapeutics, a platform company for the development of novel antifungal therapeutics. L.E.C. is a Science Advisor for Kapoose Creek, a company that harnesses the therapeutic potential of fungi. All other authors declare no competing interests.

See the funding table on p. 6.

Received 2 December 2023

Accepted 25 January 2024

Published 20 February 2024

Copyright © 2024 Fallah et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Although largely overlooked, fungal pathogens are major contributors to infectious disease, killing approximately 1.5 million people annually (1). Existing primarily as commensal members of the human mycobiota, *Candida* species can cause both superficial and life-threatening systemic infections in immunocompromised individuals (1). *Candida albicans* kills more than 400,000 individuals worldwide each year and is the fourth leading cause of nosocomial infections in the United States (1). Alarming, effective treatment of these infections is challenging due to the limited number of fungal-specific cellular targets, the increase in resistant clinical isolates, and a dearth of antifungal drug classes for the treatment of systemic infections.

The discovery of new antifungals remains a significant challenge. The Boston University Center for Molecular Discovery (BU-CMD) collection encompasses diverse chemical scaffolds of academic origin, curated in the absence of strict “drug-likeness” cutoffs (e.g., Lipinski’s rule of five or “Ro5”) and with a relaxed allowance for structural motifs known or suspected to cause pan-assay interference (e.g., “PAINS” compounds) (2–5). As a result, the collection represents an alternative to heavily curated Ro5 libraries and carries the potential for the discovery of new antimicrobials, which often exist outside of Ro5 chemical space (6). Our previous screen of a subset of the BU-CMD collection that included 2,454 compounds for antifungal activity against the fungal pathogen *Candida auris* identified molecules that inhibit translation initiation (7). Complementary work also identified a compound that potentiates azole activity against azole-resistant *Candida* species through inhibition of efflux (8).

To further interrogate the BU-CMD chemical library for antifungal activity, we screened an expanded collection of 3,049 compounds encompassing diverse chemotypes at 25 μ M in Roswell Park Memorial Institute (RPMI) 1640 medium against a clinical isolate of *C. albicans*, DPL-15 (9). Cultures were incubated at 30°C for 48 hours before growth was measured by optical density at 600 nm (OD_{600}). From this screen, 17 molecules were identified that inhibited growth of *C. albicans* >80% relative to the median growth observed in the screen (Table S1), representing a 0.55% hit rate. To verify results from the primary screen, the compounds were tested again for bioactivity against *C. albicans* using the same conditions as the primary screen, with 15 compounds displaying reproducible activity (Fig. 1A). Of those verified compounds, nine shared a similar scaffold possessing a 3-hydroxyquinolinone, whereas the other six compounds were more chemically diverse (Fig. S1).

In follow-up, we selected three of the most potent molecules to serve as representatives of the distinct chemical scaffolds identified, and used standard dose-response assays to assess their antifungal potency. CMLD013360 is a dimeric xanthone/terpenoid hybrid, generated in the course of synthetic studies toward the griffipavixanthone class of natural products (10). CMLD012661 and CMLD012693 are both 3-hydroxyquinolinones (11), a chemotype known to chelate metal ions (12). In particular, the latter two compounds have some structural similarities to iron chelators including *Pseudomonas* quinolone signal (12) and deferiprone (13). The potency of each compound was evaluated by growing the organisms in microplate format using a medium supplemented with two-fold serial dilutions of each compound as previously described (14). Growth was measured by absorbance at 600 nm (OD_{600}) after 48-hour incubation at 30°C in RPMI medium (Fig. 1B). CMLD013360, CMLD012661, and CMLD012693 all displayed activity against *C. albicans* with a minimum inhibitory concentration causing 80% growth reduction (MIC_{80}) of 25 μ M, 12.5 μ M, and 12.5 μ M, respectively. Compounds were also active against isolates of the related fungal pathogens *Candida glabrata* (MIC_{80} : 12.5 μ M, 6.25 μ M, and 6.25 μ M, respectively) and *C. auris* (MIC_{80} : 12.5 μ M, 12.5 μ M, and 25 μ M, respectively). Finally, we assessed the potency of the compounds against the evolutionarily divergent mould *Aspergillus fumigatus*. Conidial suspensions (~25,000 conidia/mL) in RPMI medium were added to 96-well plates followed by incubation at 37°C in the presence of compound for 24 hours. Subsequently, a 1:20 dilution of Alamar blue (Invitrogen) in RPMI was added to cells followed by another 24-hour incubation at 37°C (15). Fluorescence was measured (Ex. 560 nm/Em. 590 nm) to quantify metabolic activity.




FIG 1 Screening of the BU-CMD chemical library identifies compounds with activity against a clinical isolate of *C. albicans*. (A) *C. albicans* (DPL15, a caspofungin-resistant isolate) was grown in RPMI for 48 hours at 30°C with or without compounds (25 μM) from the BU-CMD library. Relative growth was measured by OD₆₀₀. Compounds were considered hits if they reduced growth >80% relative to the median growth observed in the screen. Hit compounds were tested a second time to confirm bioactivity. Growth was normalized and then calculated as a percentage of compound-free controls (see color bar). (B) Dose-response assays were performed in a 384-well plate format in technical duplicate, with two-fold dilution gradients of the three prioritized compounds against diverse fungal pathogens. Relative growth was measured by absorbance at 600 nm (OD₆₀₀) after a 48-hour incubation at 30°C in RPMI (see color bar). Data plotted represent results from one of two biological replicates that yielded similar results. (C) Dose-response assay was performed as described in (B). Standard dye reduction (Alamar blue) assay was used to measure the relative viable *Aspergillus fumigatus* cell number (see color bar). Data plotted represent results from one of two biological replicates that yielded similar results.

CMLD013360 and CMLD012693 were active against *A. fumigatus* (MIC₈₀ 50–100 μM), while CMLD012661 displayed no activity up to 100 μM , the highest concentration tested (Fig. 1B).

Exploiting metal homeostasis has been studied as a strategy to limit fungal infections (16–18). Metals have key roles in all biological systems where they are incorporated into metalloproteins, including enzymes, storage proteins, and transcription factors (19, 20). Common metallonutrients include iron, zinc, copper, calcium, manganese, and magnesium. Iron is essential to the survival of most organisms as an important cofactor for metabolic processes, as well as the transport of oxygen, activation, and

decomposition of peroxides, and the reduction of ribonucleotides and dinitrogen (21). Furthermore, in *C. albicans*, iron is required for virulence and pathogenesis (22).

Based on structural insights, CMLD013360, CMLD012661, and CMLD012693 were hypothesized to act as metal chelators (13, 23). We initially evaluated the bioactivity of our three prioritized compounds in RPMI (minimal-metal condition), yeast extract-peptone-dextrose (YPD; nutrient-rich condition), and RPMI supplemented with 10% serum (enriched-metal condition). We observed that all compounds lost bioactivity in YPD and RPMI supplemented with serum as measured by dose-response assays performed using *C. albicans* (Fig. 2A). We hypothesized that in media with increased metal content, the chelation capacity of the compounds might be exceeded and fungal growth restored. Of note, the serum-supplemented condition employed in this assay resulted in extensive *C. albicans* filamentation resulting in unreliable OD₆₀₀ measurements. Thus, the relative viable cell number was quantified by adding a 1:20 dilution of Alamar blue to wells followed by a 3-hour incubation at room temperature. Fluorescence was then measured (Ex. 560 nm/Em. 590 nm) to quantify metabolic activity (Fig. 2B).

To more specifically test the hypothesis that CMLD013360, CMLD012661, and CMLD012693 function as metal chelators, as well as narrow down the metal(s) that might be most relevant to their bioactivity, we treated *C. albicans* with inhibitory concentrations of the molecules of interest in RPMI medium supplemented specifically with an additional iron source (FeSO₄ or FeCl₃). The concentration of supplemental iron salt used for these experiments was based on results from dose-response assays defining the highest concentration that did not have a significant inhibitory effect on *C. albicans* growth (Fig. S2). Incubation of *C. albicans* with 25 μM of CMLD013360, CMLD012661, and CMLD012693, as well as 200 μM of the known iron chelator bathophenanthrolinedisulfonic acid (BPS), or 1 μg/mL of the antifungal amphotericin B significantly reduced growth relative to the untreated control (Fig. 2C). Supplementation with 1 mM FeCl₃ or 250 μM FeSO₄ restored growth of *C. albicans* in the presence of BPS or the CMLD compounds but had no effect on the antifungal activity of amphotericin B (Fig. 2C). To explore the effect of other metals on compound bioactivity, we repeated the experiment with maximal-tolerated concentrations of MnSO₄, MgSO₄, CuSO₄, and ZnSO₄. While the addition of CuSO₄ modestly rescued the growth of *C. albicans* upon incubation with CMLD013360 or CMLD012661, none of the other salts affected the potency of the CMLD compounds (Fig. 2D). Thus, CMLD013360, CMLD012661, and CMLD012693 likely exert antifungal activity by chelating iron.

Finally, to support the hypothesis that our prioritized compounds act through iron chelation, we performed dose-response assays with *C. albicans ire1Δ/ire1Δ* and *hap43Δ/hap43Δ* mutants. *IRE1* encodes a protein kinase that has an essential role in iron uptake and *C. albicans* virulence, whereas *HAP43* encodes a transcriptional regulator, which under low-iron conditions represses the expression of genes encoding iron-dependent proteins (24, 25). Given the important role of these genes in iron homeostasis, we predicted that deletion of these genes would confer hypersensitivity to compounds that chelate iron. Similar to what we observed with BPS, culture of the *ire1Δ/ire1Δ* or *hap43Δ/hap43Δ* strains with CMLD012661 and CMLD012693 resulted in eight-fold hypersensitivity to the compounds compared to their respective wild-type control strains (Fig. 2E). However, deletion of *IRE1* or *HAP43* resulted in only approximately two-fold hypersensitivity to CMLD013360 relative to wild type, suggesting this dimeric xanthone may affect iron homeostasis in a manner distinct from that of the other two compounds or may have additional non-chelation-related antifungal activities. Overall, results support the conclusion that CMLD013360, CMLD012661, and CMLD012693 exert their antifungal activity primarily through iron chelation.

In summary, this work characterizes the activity of iron chelators against important fungal pathogens. Future studies will be useful in further refining our understanding of the growth inhibitory effects of antifungal metal chelators. These insights gained could facilitate additional efforts toward the development of urgently needed new therapies to combat fungal infections.




FIG 2 CMLD12661, CMLD012693, and CMLD013360 inhibit *C. albicans* growth through iron chelation. (A) Dose-response assays of three prioritized compounds in RPMI and YPD in a 96-well plate format. Relative cell growth was assessed by absorbance at 600 nm (OD_{600}) after 48-hour incubation at 30°C (see color bar). (B) Dose-response assays of three prioritized compounds in RPMI and RPMI + 10% serum in 96-well plates. After a 48-hour incubation at 30°C, relative (Continued on next page)

FIG 2 (Continued)

metabolic activity was assessed by standard dye reduction (Alamar blue) assay (see color bar). (C) Supplementing media with additional iron salt (FeSO₄ or FeCl₃) restores fungal growth in the presence of CMLD compounds and the classical metal chelator, BPS (bathophenanthrolinedisulfonic acid). The activity of the known antifungal, amphotericin B (Amp B), was not influenced by iron supplementation. Mutant strains and their respective wild-type parental controls were grown overnight in YPD and then sub-cultured into RPMI supplemented with a concentration of the indicated compound that inhibited growth by 80% in RPMI medium alone. RPMI was also supplemented with 250 μM FeSO₄ or 1 mM FeCl₃, as indicated. Relative cell growth was assessed by absorbance at 600 nm (OD₆₀₀) after 48-hour incubation at 30°C. Bars represent the mean of technical triplicates, and error bars represent ±SD (standard deviation) of technical triplicates, *****P* ≤ 0.0001. (D) Supplementing media with metal salts (MnSO₄, MgSO₄, CuSO₄, and ZnSO₄) has no to minimal impact on the antifungal activity of compounds. Assay was performed as described in (C). Bars represent the mean of technical triplicates, and error bars represent ±SD of technical triplicates, *****P* ≤ 0.0001, and ****P* ≤ 0.001. Data plotted represent results from one of two biological replicates that yielded similar results. (E) Deletion of *IRE1* or *HAP43* increases the bioactivity of CMLD013360, CMLD012661, and CMLD012693 against *C. albicans*. Parental wild-type strains, and *ire1Δ/ire1Δ* and *hap43Δ/hap43Δ* mutant strains, were grown overnight in YPD and then subjected to dose-response assays in RPMI medium with two-fold dilution gradients of CMLD013360, CMLD012661, and CMLD012693. BPS, a metal chelator, was included as a positive control. Relative cell growth was assessed by a standard dye reduction (Alamar blue) assay after 48-hour incubation at 30°C. For all dose-response assays, growth was averaged between technical duplicates and normalized to drug-free control wells. Heat maps plotted are representative of two biological replicates.

ACKNOWLEDGMENTS

We thank all past and current Cowen lab members for helpful discussions. L.E.C. is supported by the Canadian Institutes of Health Research (CIHR) Foundation grant (FDN-154288), is a Canada Research Chair (Tier 1) in Microbial Genomics & Infectious Disease, and co-Director of the CIFAR Fungal Kingdom: Threats & Opportunities program. Work at the BU-CMD (L.E.B. and J.A.P.) is supported by NIH U01 TR002625 and R35 GM 118173.

AUTHOR AFFILIATIONS

¹Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada

²Department of Chemistry, Brock University, St. Catharines, Ontario, Canada

³Department of Chemistry, Center for Molecular Discovery (BU-CMD), Boston University, Boston, Massachusetts, USA

PRESENT ADDRESS

Dustin Duncan, Department of Chemistry, Brock University, St. Catharines, Canada

AUTHOR ORCID*s*

Sara Fallah  <http://orcid.org/0009-0002-1755-2656>

Nicole Robbins  <http://orcid.org/0000-0001-5797-0110>

Leah E. Cowen  <http://orcid.org/0000-0001-5797-0110>

FUNDING

Funder	Grant(s)	Author(s)
Canadian Government Canadian Institutes of Health Research (IRSC)	FDN-154288	Leah E. Cowen
HHS National Institutes of Health (NIH)	U01 TR002625	Lauren E. Brown
HHS National Institutes of Health (NIH)	R35 GM 118173	Lauren E. Brown

AUTHOR CONTRIBUTIONS

Sara Fallah, Conceptualization, Formal analysis, Investigation, Visualization, Writing – original draft | Dustin Duncan, Investigation, Writing – review and editing | Kyle D. Reichl, Resources | Michael J. Smith, Resources | Wenyu Wang, Resources | John A. Porco Jr., Funding acquisition, Resources, Writing – review and editing | Lauren E. Brown, Funding

acquisition, Resources, Writing – review and editing | Luke Whitesell, Conceptualization, Supervision, Writing – review and editing | Nicole Robbins, Conceptualization, Supervision, Writing – review and editing.

ADDITIONAL FILES

The following material is available [online](#).

Supplemental Material

Fig S1 and Fig S2 (Spectrum04095-23-s0001.pdf). Supplemental figures with legends.
Table S1 (Spectrum04095-23-s0002.xlsx). Chemical screen results.

REFERENCES

- Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. 2012. Hidden killers: human fungal infections. *Sci Transl Med* 4:165rv13. <https://doi.org/10.1126/scitranslmed.3004404>
- Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced Drug Delivery Reviews* 23:3–25. [https://doi.org/10.1016/S0169-409X\(96\)00423-1](https://doi.org/10.1016/S0169-409X(96)00423-1)
- Baell JB. 2016. Feeling nature's PAINS: natural products, natural product drugs, and pan assay interference compounds (PAINS). *J Nat Prod* 79:616–628. <https://doi.org/10.1021/acs.jnatprod.5b00947>
- Baell JB, Holloway GA. 2010. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. *J Med Chem* 53:2719–2740. <https://doi.org/10.1021/jm901137j>
- Pouliot M, Jeanmart S. 2016. Pan assay interference compounds (PAINS) and other promiscuous compounds in antifungal research. *J Med Chem* 59:497–503. <https://doi.org/10.1021/acs.jmedchem.5b00361>
- Shultz MD. 2019. Two decades under the influence of the rule of five and the changing properties of approved oral drugs. *J Med Chem* 62:1701–1714. <https://doi.org/10.1021/acs.jmedchem.8b00686>
- Iyer KR, Whitesell L, Porco JA, Henkel T, Brown LE, Robbins N, Cowen LE. 2020. Translation inhibition by rocglates activates a species-specific cell death program in the emerging fungal pathogen *Candida auris*. *mBio* 11:e03329-19. <https://doi.org/10.1128/mBio.03329-19>
- Iyer KR, Camara K, Daniel-Ivad M, Trilles R, Pimentel-Elardo SM, Fossen JL, Marchillo K, Liu Z, Singh S, Muñoz JF, Kim SH, Porco JA, Cuomo CA, Williams NS, Ibrahim AS, Edwards JE, Andes DR, Nodwell JR, Brown LE, Whitesell L, Robbins N, Cowen LE. 2020. An oxindole efflux inhibitor potentiates azoles and impairs virulence in the fungal pathogen *Candida auris*. *Nat Commun* 11:6429. <https://doi.org/10.1038/s41467-020-20183-3>
- Singh SD, Robbins N, Zaas AK, Schell WA, Perfect JR, Cowen LE, Mitchell AP. 2009. Hsp90 governs echinocandin resistance in the pathogenic yeast *Candida albicans* via calcineurin. *PLoS Pathog* 5:e1000532. <https://doi.org/10.1371/journal.ppat.1000532>
- Smith MJ. 2021. Syntheses of griffipavixanthone and related dimeric xanthenes using para-quinone methides. Doctor of Philosophy. Boston University.
- Wang W, Cencic R, Whitesell L, Pelletier J, Porco JA. 2016. Synthesis of aza-rocglates via ESIPT-mediated (3+2) photocycloaddition. *Chemistry* 22:12006–12010. <https://doi.org/10.1002/chem.201602953>
- Bredenbruch F, Geffers R, Nimtz M, Buer J, Häussler S. 2006. The *Pseudomonas aeruginosa* quinolone signal (PQS) has an iron-chelating activity. *Environ Microbiol* 8:1318–1329. <https://doi.org/10.1111/j.1462-2920.2006.01025.x>
- Entezari S, Haghi SM, Norouzkhani N, Saheb nazari B, Vosoughian F, Akbarzadeh D, Islampannah M, Naghsh N, Abbasalizadeh M, Deravi N. 2022. Iron chelators in treatment of iron overload. *J Toxicol* 2022:4911205. <https://doi.org/10.1155/2022/4911205>
- Xie J, Singh-Babak S, Cowen L. 2012. Minimum inhibitory concentration (MIC) assay for antifungal drugs. *Bio-protocol* 2:e252. <https://doi.org/10.21769/BioProtoc.252>
- Puumala E, Zaslaver O, Chen A, Duncan D, Fogal M, Shapiro RS, Mazhab-Jafari MT, Whitesell L, Montenegro-Burke JR, Robbins N, Cowen LE, Bahn Y-S. 2022. The trisubstituted Isoxazole MMV688766 exerts broad-spectrum activity against drug-resistant fungal pathogens through inhibition of lipid homeostasis. *mBio* 13:e0273022. <https://doi.org/10.1128/mbio.02730-22>
- Hameed S, Hans S, Singh S, Fatima Z. 2020. Harnessing metal homeostasis offers novel and promising targets against *Candida albicans*. *Curr Drug Discov Technol* 17:415–429. <https://doi.org/10.2174/1570163816666190227231437>
- Polvi EJ, Averette AF, Lee SC, Kim T, Bahn YS, Veri AO, Robbins N, Heitman J, Cowen LE. 2016. Metal chelation as a powerful strategy to probe cellular circuitry governing fungal drug resistance and morphogenesis. *PLoS Genet* 12:e1006350. <https://doi.org/10.1371/journal.pgen.1006350>
- Sonthalia S, Agrawal M, Sehgal VN. 2019. Topical ciclopirox olamine 1%: revisiting a unique antifungal. *Indian Dermatol Online J* 10:481–485. https://doi.org/10.4103/idoj.IDOJ_29_19
- Bleackley MR, Macgillivray RTA. 2011. Transition metal homeostasis: from yeast to human disease. *Biomaterials* 24:785–809. <https://doi.org/10.1007/s10534-011-9451-4>
- Hood MI, Skaar EP. 2012. Nutritional immunity: transition metals at the pathogen-host interface. *Nat Rev Microbiol* 10:525–537. <https://doi.org/10.1038/nrmicro2836>
- Pierre JL, Fontecave M, Crichton RR. 2002. Chemistry for an essential biological process: the reduction of ferric iron. *Biomaterials* 15:341–346. <https://doi.org/10.1023/a:1020259021641>
- Noble SM. 2013. *Candida albicans* specializations for iron homeostasis: from commensalism to virulence. *Curr Opin Microbiol* 16:708–715. <https://doi.org/10.1016/j.mib.2013.09.006>
- Yang A, Yu Q, Ju H, Song L, Kou X, Shen R. 2020. Design, synthesis and biological evaluation of xanthone derivatives for possible treatment of Alzheimer's disease based on multi-target strategy. *Chem Biodivers* 17:e2000442. <https://doi.org/10.1002/cbdv.202000442>
- Ramírez-Zavala B, Krüger I, Dunker C, Jacobsen ID, Morschhäuser J. 2022. The protein kinase Ire1 has a Hac1-independent essential role in iron uptake and virulence of *Candida albicans*. *PLoS Pathog* 18:e1010283. <https://doi.org/10.1371/journal.ppat.1010283>
- Hsu PC, Yang CY, Lan CY. 2011. *Candida albicans* Hap43 is a repressor induced under low-iron conditions and is essential for iron-responsive transcriptional regulation and virulence. *Eukaryot Cell* 10:207–225. <https://doi.org/10.1128/EC.00158-10>